Hershey Co. (NYSE:HSY) announced sales and earnings for the fourth quarter ended December 31, 2010. Consolidated net sales were $1,482,809,000 compared with $1,407,336,000 for the fourth quarter of 2009. Reported net income for the fourth quarter of 2010 was $135,513,000 or $0.59 per share-diluted, compared with $126,779,000 or $0.55 per share-diluted for the comparable period of 2009.

The Hershey Company, together with its subsidiaries, engages in manufacturing, marketing, selling, and distributing various chocolate and confectionery products, pantry items, and gum and mint refreshment products worldwide.

**********************************************

National Health Partners, Inc. (NHPR.OB) is a leading national healthcare savings organization that provides unique discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress."

National Health Partners currently offer five standard CARExpress membership programs that provide benefits that range from prescription drug and vision care to comprehensive physician, hospital, vision, dental and other care.

Comprehensive Care Program.This program is designed for individuals and families with little or no health insurance. It provides members with access to all of our CARExpress products and services, including physician, hospital and ancillary care, dental and vision care, retail and mail order pharmacy, 24-hour nurseline, hearing care, chiropractic and complementary alternative care, medical supplies and equipment, and long-term care facilities. The monthly retail price for this membership program is $39.95 per family.

Supplemental Care Program.This program is designed for individuals and families who are underinsured and offers everything our comprehensive care program offers, except for access to doctors and hospitals. Our supplemental care program generally presumes the member has some level of basic medical insurance coverage. The monthly retail price for this membership program is $29.95 per family.

Preferred Care / Senior Advantage Program. This program is designed for individuals and families who are underinsured and need to save on the basic health services not covered under a traditional health insurance plan. It offers savings on prescriptions, vision and dental care, and a 24-hour nurseline. The monthly retail price for this membership program is $19.95 per family.

Dental & Vision Care Program. This program is designed for individuals and families who typically have health insurance, but who do not have either dental care or vision care. The monthly retail price for this membership program is $14.95 per family.

Prescription & Vision Care Program. This program is designed to offer members an inexpensive way to save money on prescriptions and vision care. This program is our low-cost entry program. The monthly retail price for this program is $9.95 per family.

National Health Partners, Inc., a national healthcare membership organization, creates, markets, and sells membership programs to underserved markets in the healthcare industry in the United States. Its programs provide an alternative to individuals who seek to reduce their healthcare costs not covered by insurance, or who are unable to obtain healthcare insurance due to their medical history, age, or occupation. The company, through its CARExpress membership programs, offers CARExpress health discount programs and CARExpress Plus membership programs. National Health Partners CARExpress health discount programs cover various aspects of healthcare, including physicians, hospitals, ancillary services, dentists, prescription drugs, vision care, hearing aids, chiropractic services, alternative care, 24-hour nurseline, medical supplies, and equipment, as well as long-term care facilities, which include skilled nursing facilities, assisted living facilities, respite care, and home health care.

For more information on the company, please visit its website at www.nationalhealthpartners.com.

************************************************************

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) is a commercial healthcare company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets, including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country-specific regulatory clearances and approvals.

Oculus Innovative Sciences, Inc. announced that it has received a new FDA 510(k) clearance for its uniquely formulated Microcyn-based Epicyn™ HydroGel. Under the supervision of a healthcare professional, it is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis and radiation dermatitis. Epicyn HydroGel may also be used to relieve the pain of first- and second-degree burns and can help to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process. The hydrogel is a shelf-stable hypochlorous acid formulation based on the company’s proprietary Microcyn Technology platform.

“Our newly approved dermatology indication opens two interesting new markets to Oculus — atopic dermatitis, which afflicts 15 million U.S. patients, and radiation dermatitis, with over one million U.S. patients. The use of the proprietary Microcyn Technology for these challenging skin afflictions is truly a unique approach and adds both depth and breadth to Oculus’ dermatology product portfolio,” said Hoji Alimi, founder and CEO of Oculus. “And in line with our business strategy, we plan to partner this new indication at the earliest for faster commercialization.”

More than 15 million patients have symptoms of atopic dermatitis, characterized by itchy skin, which can lead to rash, redness, swelling, crusting and scaling. The disease affects up to 20 percent of infants and young children, who continue to have symptoms as adults with significant impact on their quality of life. The exact cause is unknown, but genetics are considered a key factor.

A wide variety of products have been used to treat radiation dermatitis with little or no evidence to support their use. According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide, of which 5.6 million occurred in economically developed countries and 7.1 million in economically developing countries. Of the total cancer patients, approximately 60 percent receive radiation treatment, and up to 95% of those are afflicted with radiation dermatitis.

Oculus Innovative Sciences headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America.

More information can be found at www.oculusis.com.

**********************************************

Hitachi Ltd. (NYSE:HIT) announced that the appointment of Takashi Hatchoji as Group Chairman for the Americas, Hitachi Ltd., and Chairman of Hitachi America, Ltd., effective on April 1, 2011. He is also scheduled to be appointed as a Director at Hitachi’s Ordinary General Meeting of Shareholders in late June. Tadahiko Ishigaki, currently Senior Vice President and Executive Officer, Chief Executive for the Americas and Chairman of Hitachi America, Ltd., will return to Japan working with Hitachi, Ltd., effective on April 1, 2011.

Hitachi, Ltd. manufactures and sells electronic and electrical products primarily in Asia, North America, and Europe. Its Information & Telecommunication Systems segment provides systems integration, outsourcing services, software, disk array subsystems, servers, mainframes, telecommunications equipment, and ATMs.

**********************************************

Manpower Inc. (NYSE:MAN) reported a net loss of $4.29 per diluted share for the three months ended December 31, 2010 compared to net earnings of 37 cents in the prior year period. The net loss in the quarter was $350.4 million compared to net earnings of $29.1 million a year earlier. Revenues for the fourth quarter totaled $5.2 billion, an increase of 18 percent from the year earlier period, or an increase of 22 percent in constant currency.

Manpower Inc. provides employment services primarily in the United States, Canada, England, Germany, the Netherlands, South Africa, and Hong Kong.

****************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and anticipates receiving 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (NHPR.OB).